Ustekinumab vs Guselkumab: side effects in FDA adverse event reports
At a glance
| Ustekinumab | Guselkumab | |
|---|---|---|
| Drug class | Interleukin-12 Antagonist, Interleukin-23 Antagonist | Interleukin-23 Antagonist |
| Brand names | – | Tremfya |
| FAERS reports | 101,629 | 35,198 |
| Serious | 59% | 26% |
| Death outcome | 5,950 | 458 |
| Boxed warning | No | No |
Signals both drugs share
No strong shared signal after removing coding and lab terms.
Labeled signals distinctive to Ustekinumab
- Peripheral venous disease — n=1,058, PRR 74.2 Labeled (related wording)
- Contraindication to vaccination — n=42, PRR 57.8 Labeled (related wording)
Labeled signals distinctive to Guselkumab
- Latent tuberculosis — n=33, PRR 9.5 Labeled (related wording)
Common questions
Which has more reported side effects, Ustekinumab or Guselkumab?
Ustekinumab has 101,629 FAERS reports and Guselkumab 35,198. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (59% vs 26%) is a better like-for-like signal of the kind of problems reported.
Which side effects do Ustekinumab and Guselkumab share?
They share no strong flagged signal after artifacts and lab terms are removed.
Is Ustekinumab or Guselkumab safer?
FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.
Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.